Dr. Clay Siegall Of Seattle Genetics Shares The Latest NFL News

Dr. Clay Siegall linked an ESPN article on his official blog about the Buffalo Bills. The Tennessee Titans had fired their offensive coach, Terry Robiskie. He was picked up on 2-14-18 as the Bills wide receivers coach. This is considered a huge hire as he is a very good coach for that position. It’s been said that its this position that he is most comfortable coaching rather than the entire offense.

Another article was about Quarterback Jimmy Garoppolo who plays for the San Francisco 49ers. Nick Wagoner of ESPN said that with this offseason Garoppolo will be able to really dive into the offense that head coach and offensive coordinator runs. He didn’t have much time to learn it last year as he was a late-season addition to the team. Despite this he completely turned the offense around to where they were playing far better than they had been before his arrival.

Dr. Clay Siegall enjoys sharing sports and science news with the readers of his blog. He is an entrepreneur who co-founded Seattle Genetics. His company creates targeted drugs in order to treat cancer patients. His first drug that was approved by the Federal Drug Administration is called Adcetris. This drug cures two forms of lymphoma and has saved thousands of people around the world since it was approved for usage.

As the chief executive officer of his company, Dr. Clay Siegall is responsible for entering into strategic licenses for the technology his company creates. He has signed over $350 million in these contracts including with companies like GlaxoSmithKline, AbbVie, Genentech, and Pfizer among others. His company has over 20 types of drugs currently in different stages of research and development.

Dr. Clay Siegall says that collaboration is key to the success of Seattle Genetics. He works with other industry leaders including those engaged in oncology drug development. These collaborations sharing their antibody drug conjugate have given his team the resources to develop new ideas and apply new approaches to helping those who are diagnosed with cancer.